Administration of either CXCR4 neutralizing antibody or CXCR4 siRNA impairs the enhanced glioma malignancy (proliferation, angiogenesis, invasion, metastasis, and postchemotherapy and postradiotherapy recurrence) and increases median survival in vivo glioma models [17–20, 22–27]. Here, CXCR4 is linked to central nervous system cancer.